Global chloroquine products market is expected to grow at a CAGR of 4.0% to 2027Published Date: April 17, 2021 |
Chloroquine exerts its pharmacological effect by inhibiting the action of heme polymerase which eventually results in the buildup of toxic heme in the plasmodium species. It also passively diffuses through the cell membrane and hence becomes protonated and raises the surrounding pH which prevents the virus particles in fusing and entering the cell and hence is currently being studied for its therapeutic efficacy in COVID-19 infection.
Browse the full report Chloroquine Products Market – Growth, Future Prospects, Competitive Analysis, 2021 – 2027 report at https://www.researchcorridor.com/chloroquine-products-market/
Protozoan infection are spearheading the clinical application segment for the chloroquine products market. Malaria is causes by the plasmodium species such as vivax, ovale, falciparum and malaria, as per the latest statistics provided by the World Health Organization (WHO) in 2018, approximately 405 000 deaths due to malaria infection were reported worldwide. Sub-Saharan Africa, South Asia and tropical rain forest are the regions were the highest mortality rate has been reported due to lack of medical provisions. Amebiasis is caused by the protozoan parasite Entamoeba histolytica in which transmission is caused by the feacal oral route, according to the latest information provided by the National Institute of Health (NIH), each year approximately 50 million cases of invasive E. histolytica infection are reported worldwide. Autoimmune diseases are expected to showcase sturdy market growth in the near future owing to the rising incidence of lupus erythematosus in the developed regions.
Hospital pharmacy is presently leading the distribution channel segment for the chloroquine products market. The long duration of action and half-life of 20 to 60 days makes it imperative for accurate medicine dispensing by hospital pharmacist to prevent the occurrence of drug related adverse events. Retail pharmacy is keen to register remarkable market growth during the forecast period owing to the Avaialbity of government subsidized low cost generic medicines in the developing region.
Asia Pacific is currently dominating the geography segment for chloroquine products market. Rising prevalence of protozoan infection in the South East Asia region primarily drives the market growth. Poor sanitation, unhygienic food and water are the primary causes for the occurrence of amoebiasis in the slum dwellings of the South Asian countries. Developing healthcare infrastructure and effective implementation of the treatment guidelines pertaining to protozoan infections together accentuate the market growth in the region. Latin America is 2nd in the regional segment on account of the plasmodium species infection in the far flung rain forest areas. North America is anticipated to be the fastest growing regional segment for chloroquine products market. Developed healthcare infrastructure and existence of major players such as Bayer AG, Sandoz, Inc., Teva Pharmaceutical Industries Ltd., etc determines the chloroquine products market growth in the region.
To know more about the study, request a report sample
Pharmaceutical manufacturers actively engaged in the production of chloroquine products are Recipharm AB, Bayer AG, Sandoz, Inc., Teva Pharmaceutical Industries Ltd., Sanofi Aventis, IPCA Laboratories, Cadila Healthcare, Merck & Co., Inc., Indofarma and Alliance Pharmaceuticals.
Key Market Movements:
- Rising prevalence of protozoan infection worldwide
- Growing incidence of autoimmune diseases throughout the globe further accentuates the market growth
- Nurturing regulatory environment provided by the global healthcare agencies for the sale and distribution of chloroquine products further drive the market growth
Contact Person: Mr. Vijendra Singh
Contact Email: email@example.com
- Global chromosome enumeration probes market is expected to grow at a CAGR of 7.1% to 2027
- Global dried aluminium hydroxide gels market is expected to grow at a CAGR of 3.6% to 2027
- Global chloroquine products market is expected to grow at a CAGR of 4.0% to 2027
- Global epoprostenol market is expected to grow at a CAGR of 3.0% to 2027
- Global ganciclovir market is expected to grow at a CAGR of 6.1% to 2027